Dr Agarwals Eye Hospital Ltd Stock Price Today (NSE: DRAGARWQ)
Fundamental Score
Dr Agarwals Eye Hospital Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Dr Agarwals Eye Hospital Ltd share price today is ₹4776.00, up +0.00% on NSE/BSE as of 17 February 2026. Dr Agarwals Eye Hospital Ltd (DRAGARWQ) is a Small-cap company in the Hospital sector with a market capitalisation of ₹2.78K (Cr). The 52-week high for DRAGARWQ share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 44.20x, DRAGARWQ is currently trading below its industry average P/E of 52.84x. The company has a Return on Equity (ROE) of 29.50% and a debt-to-equity ratio of 1.06.
Dr Agarwals Eye Hospital Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Dr Agarwals Eye Hospital Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis of Dr Agarwals Eye Hospital Share Price
The Indian hospital sector is currently experiencing robust growth fueled by increasing healthcare awareness and access, especially in Tier 2 and Tier 3 cities. This analysis delves into the financial health of Dr. Agarwal's Eye Hospital Ltd, focusing on their current valuation and profitability metrics. This report examines the recent Dr Agarwals Eye Hospital share price of ₹4688.899902, alongside other key financial indicators to ascertain the company’s financial stability.
The Price-to-Earnings (PE) ratio for Dr. Agarwal's Eye Hospital stands at 44.2. This suggests investors are willing to pay ₹44.2 for every rupee of earnings, indicating a potentially high growth expectation or an overvalued scenario. It is important to compare this PE ratio with its sector peers. For instance, a deeper dive into
Nephro Care India Limited's management quality and capital allocation strategies could provide a comparative benchmark, highlighting whether Dr. Agarwal's premium is justified by superior operational efficiency or growth prospects.A crucial factor in assessing Dr. Agarwal's long-term sustainability is its Return on Capital Employed (ROCE) of 17.53%. This metric indicates the efficiency with which the company utilizes its capital to generate profits. A higher ROCE often signifies a stronger competitive advantage or “moat.” In Dr. Agarwal's case, a ROCE of 17.53% suggests that the company is effectively deploying its capital to generate returns, reinforcing its position within the specialized eye care market. This can be a significant differentiator compared to peers like Strategic Minerals Plc or Abateas Industries Ltd, operating in potentially different sectors with varying capital intensity.
It's important to contextualize these figures. A high PE ratio might be justified if future growth prospects are significantly higher than peers. Conversely, a sustainable ROCE contributes to building a strong financial foundation, enabling reinvestment in growth initiatives and potentially shareholder value creation. This financial analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, providing a detailed assessment of Dr. Agarwal's Eye Hospital Ltd's financial stability based on publicly available data. This analysis uses observational language and does not constitute financial advice or a recommendation to buy or sell shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Agarwals Eye Hospital Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of DRAGARWQ across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (29.50%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.53%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (28.53%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (36.54%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (15.20%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (17.68% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (32.05% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (32.05% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.58x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹43.95 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (72.67%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 44.20x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Elevated Debt Levels (D/E: 1.06)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Limited Institutional Interest (FII+DII: 4.10%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
High Share Pledging Risk (29.26%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Dr Agarwals Eye Hospital Ltd Financial Statements
Comprehensive financial data for Dr Agarwals Eye Hospital Ltd including income statement, balance sheet and cash flow
About DRAGARWQ (Dr Agarwals Eye Hospital Ltd)
Dr Agarwals Eye Hospital Ltd (DRAGARWQ) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a current market capitalisation of ₹2.78K (Cr). Dr Agarwals Eye Hospital Ltd has delivered a Return on Equity (ROE) of 29.50% and a ROCE of 17.53%. The debt-to-equity ratio stands at 1.06, reflecting the company's capital structure. Investors tracking DRAGARWQ share price can monitor key metrics including P/E ratio, promoter holding of 72.67%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
DRAGARWQ Share Price: Frequently Asked Questions
What is the current share price of Dr Agarwals Eye Hospital Ltd (DRAGARWQ)?
As of 17 Feb 2026, 10:09 am IST, Dr Agarwals Eye Hospital Ltd share price is ₹4776.00. The DRAGARWQ stock has a market capitalisation of ₹2.78K (Cr) on NSE/BSE.
Is DRAGARWQ share price Overvalued or Undervalued?
DRAGARWQ share price is currently trading at a P/E ratio of 44.20x, compared to the industry average of 52.84x. Based on this relative valuation, the Dr Agarwals Eye Hospital Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of DRAGARWQ share price?
The 52-week high of DRAGARWQ share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Dr Agarwals Eye Hospital Ltd share price?
Key factors influencing DRAGARWQ share price include quarterly earnings growth (Sales Growth: 15.20%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Dr Agarwals Eye Hospital Ltd a good stock for long-term investment?
Dr Agarwals Eye Hospital Ltd shows a 5-year Profit Growth of 32.05% and an ROE of 29.50%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.06 before investing in DRAGARWQ shares.
How does Dr Agarwals Eye Hospital Ltd compare with its industry peers?
Dr Agarwals Eye Hospital Ltd competes with major peers in the Hospital. Investors should compare DRAGARWQ share price P/E of 44.20x and ROE of 29.50% against the industry averages to determine competitive standing.
What is the P/E ratio of DRAGARWQ and what does it mean?
DRAGARWQ share price has a P/E ratio of 44.20x compared to the industry average of 52.84x. Investors pay ₹44 for every ₹1 of annual earnings.
How is DRAGARWQ performing according to Bull Run's analysis?
DRAGARWQ has a Bull Run fundamental score of 52.8/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does DRAGARWQ belong to?
DRAGARWQ operates in the Hospital industry. This classification helps understand the competitive landscape and sector-specific trends affecting Dr Agarwals Eye Hospital Ltd share price.
What is Return on Equity (ROE) and why is it important for DRAGARWQ?
DRAGARWQ has an ROE of 29.50%, which indicates excellent management efficiency. ROE measures how efficiently Dr Agarwals Eye Hospital Ltd generates profits from shareholders capital.
How is DRAGARWQ debt-to-equity ratio and what does it indicate?
DRAGARWQ has a debt-to-equity ratio of 1.06, which indicates high leverage that increases financial risk.
What is DRAGARWQ dividend yield and is it a good dividend stock?
DRAGARWQ offers a dividend yield of 0.10%, meaning you receive ₹0.10 annual dividend for every ₹100 invested in Dr Agarwals Eye Hospital Ltd shares.
How has DRAGARWQ share price grown over the past 5 years?
DRAGARWQ has achieved 5-year growth rates of: Sales Growth 17.68%, Profit Growth 32.05%, and EPS Growth 32.05%.
What is the promoter holding in DRAGARWQ and why does it matter?
Promoters hold 72.67% of DRAGARWQ shares, with 29.26% pledged. High promoter holding often indicates strong management confidence in Dr Agarwals Eye Hospital Ltd.
What is DRAGARWQ market capitalisation category?
DRAGARWQ has a market capitalisation of ₹2783 crores, placing it in the Small-cap category.
How volatile is DRAGARWQ stock?
DRAGARWQ has a beta of N/A. A beta > 1 suggests the Dr Agarwals Eye Hospital Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is DRAGARWQ operating profit margin trend?
DRAGARWQ has a 5-year average Operating Profit Margin (OPM) of 28.53%, indicating the company's operational efficiency.
How is DRAGARWQ quarterly performance?
Recent quarterly performance shows Dr Agarwals Eye Hospital Ltd YoY Sales Growth of 15.20% and YoY Profit Growth of 36.54%.
What is the institutional holding pattern in DRAGARWQ?
DRAGARWQ has FII holding of 1.74% and DII holding of 2.36%. Significant institutional holding often suggests professional confidence in the Dr Agarwals Eye Hospital Ltd stock.